Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Smith & Nephew monthly revenue nearly halves as most markets stop non-emergency surgery

Procedures are starting to return in some countries, including the US, while China has shown improved trading

Smith & Nephew PLC (LON:SN.) said revenue in April plunged 47% as most of its markets have stopped non-emergency surgery amid the coronavirus pandemic.

The medical products manufacturer said that these procedures are starting to return in some countries, including the US, while China has shown improved trading.

READ: Smith & Nephew weak as Citigroup downgrades to ‘neutral’ citing impact of coronavirus pandemic

In the quarter to 28 March revenue slipped 8% to US$1.3bn.

The FTSE 100-listed firm has implemented measures to save up to US$200mln, while it had US$1.8bn of net debt at the end of the quarter with US$3.4bn of committed facilities.

Shares rose 2% to 1,622p on Wednesday in early trades.

--Adds shares--

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK